# Assessing the Reliability of D-Dimer Measurement in EDTA Plasma: A Comparison to the Established Citrate Method

**Authors:** Daniel Pfingst, Adriana Méndez, Peter Neyer, Henning Nilius, Nicole Schaub, Patricia Keusch, Michael Nagler, Angelika Hammerer-Lercher

PMC · DOI: 10.3390/diagnostics15131720 · Diagnostics · 2025-07-06

## TL;DR

This study compares D-dimer measurements in EDTA and citrate plasma, finding that EDTA can be a viable alternative when citrate is unavailable.

## Contribution

The study demonstrates the feasibility of using EDTA plasma as an alternative to citrate plasma for D-dimer testing.

## Key findings

- The correlation between D-dimer measurements in citrate and EDTA plasma was strong (r ≥ 0.96).
- EDTA plasma can provide similar diagnostic information to citrate plasma after correcting for dilution effects.

## Abstract

Background: D-dimer determined in citrated plasma is a well-established and efficient biomarker, particularly for ruling out venous thromboembolism. In certain clinical settings, the availability of citrated plasma may pose challenges when not readily available. To address this issue, we investigated the feasibility of using ethylenediaminetetraacetic acid (EDTA) plasma as an alternative specimen for D-dimer measurement. Methods: Our study evaluated anonymized plasma samples (n = 99, for both citrate and EDTA) using the INNOVANCE® D-dimer assay, an automated particle-enhanced immunoassay, and the INNOVANCE® LOCI hs D-dimer assay, leveraging the luminescent oxygen channeling assay (LOCI) method. Results: The assays demonstrated a correlation of r ≥ 0.97 (95% CI 0.96 to 0.98) within citrated plasma and maintained a similar correlation r ≥ 0.96 (95% CI 0.94 to 0.97) between citrate and EDTA plasma upon correction for the dilution effect of the sodium citrate solution. Conclusions: These results indicate that the utilization of EDTA instead of citrate plasma is feasible and may provide similar diagnostic information. However, the observed variance could have an impact on clinical interpretation and risk assessment. Therefore, future studies are needed to confirm the results and, if necessary, determine cut-off values and clinical performance.

## Linked entities

- **Chemicals:** ethylenediaminetetraacetic acid (PubChem CID 6049), sodium citrate (PubChem CID 6224)
- **Diseases:** venous thromboembolism (MONDO:0005399)

## Full-text entities

- **Diseases:** venous thromboembolism (MESH:D054556)
- **Chemicals:** Citrate (MESH:D019343), sodium citrate (MESH:D000077559), oxygen (MESH:D010100), EDTA (MESH:D004492)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12248503/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12248503/full.md

## References

15 references — full list in the complete paper: https://tomesphere.com/paper/PMC12248503/full.md

---
Source: https://tomesphere.com/paper/PMC12248503